Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 12/20 | 0.49 |
| ▸ | BCHE | P06276 | 9/20 | 0.46 |
| ▸ | EBP | Q15125 | 5/20 | 0.44 |
| ▸ | DHCR7 | Q9UBM7 | 5/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.36 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26499565 | 1.00 | ACHE (0.49) | ACHEBCHEEBPDHCR7GABRA1 | |
| SCHEMBL22072575 | 0.87 | GABRA1 (0.50) | ACHEBCHEEBPDHCR7GABRA1 | |
| SCHEMBL22072577 | 0.87 | GABRA1 (0.50) | ACHEBCHEEBPDHCR7GABRA1 | |
| SCHEMBL28630490 | 0.87 | GABRA1 (0.50) | ACHEBCHEEBPDHCR7GABRA1 | |
| SCHEMBL25050361 | 0.87 | GABRA1 (0.50) | ACHEBCHEEBPDHCR7GABRA1 | |
| SCHEMBL25052039 | 0.87 | GABRA1 (0.50) | ACHEBCHEEBPDHCR7GABRA1 | |
| SCHEMBL22033310 | 0.87 | GABRA1 (0.50) | ACHEBCHEEBPDHCR7GABRA1 | |
| SCHEMBL25050363 | 0.87 | GABRA1 (0.50) | ACHEBCHEEBPDHCR7GABRA1 | |
| SCHEMBL22033309 | 0.87 | GABRA1 (0.50) | ACHEBCHEEBPDHCR7GABRA1 | |
| SCHEMBL28630492 | 0.87 | GABRA1 (0.50) | ACHEBCHEEBPDHCR7GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912738-B2 | Neuroactive steroids and their methods of use | SAGE THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230322849-A1 | NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | SAGE THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322849-A1 | NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | NR3C2, MC2R, NR3C1 | ACHE 142/4885BCHE 645/4885EBP 655/4885 |
| US-11912738-B2 | Neuroactive steroids and their methods of use | NR3C2, MC2R, NR3C1 | ACHE 142/4885BCHE 645/4885EBP 655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.